ScreenerHero

EGRXEagle Pharmaceuticals, Inc.

NAS · US · Healthcare · Drug Manufacturers - Specialty & Generic · eagleus.com
0.5300USD-10.92%Mkt Cap: 3.29M $P/E: 1.79

Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on manufacturing, developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology …

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
MERCK Kommanditgesellschaft auf Aktien
$65.19BUSDP/E 23.7
TAK
Takeda Pharmaceutical Co. Ltd.
$58.06BUSD
HLN
Haleon plc American Depositary Shares (Each representing two Ordinary Shares)
$43.98BUSDP/E 20.4
TEVA
Teva Pharmaceutical Industries Limited
$43.51BUSDP/E 62.2
ZOE
Zoetis Inc.
$29.89BUSDP/E 12.7
ZTS
Zoetis Inc.
$32.12BUSDP/E 12.7
UTHR
United Therapeutics Corporation
$22.01BUSDP/E 18.4
VTRS
Viatris, Inc.
$18.75BUSD
SOBI
Swedish Orphan Biovitrum AB
$15.34BUSDP/E 117.3
IPN
Ipsen S.A.
$14.67BUSDP/E 26.4
NBIX
Neurocrine Biosciences, Inc.
$15.51BUSDP/E 22.3
ELAN
Elanco Animal Health Incorporat
$11.98BUSD
RDY
Dr. Reddy's Laboratories Ltd
$10.15BUSDP/E 29.7
KRK
Krka, d. d.
$8.66BUSDP/E 19.0
ALKS
Alkermes plc
$8.11BUSDP/E 127.2
HIMS
Hims & Hers Health, Inc.
$7.88BUSD
LNTH
Lantheus Holdings Inc
$6.53BUSDP/E 23.9
AMRX
Amneal Pharmaceuticals, Inc. Class A
$6.24BUSDP/E 37.3
LQDA
Liquidia Corporation
$6.14BUSDP/E 49.0
KNSA
Kiniksa Pharmaceuticals, Ltd.
$6.08BUSDP/E 79.8

Key Statistics

Company
Market Cap3.29M $
Enterprise Value63.98M $
Revenue (TTM)257.55M $
Gross Profit221.67M $
Net Income (TTM)35.64M $
Revenue/Share19.68 USD
Last Price0.5300 USD
Fiscal Year EndDec 2022
MR QuarterJun 2023
Employees134
CountryUS
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISINUS2697961082
Valuation
P/E (Trailing)1.79
P/E (Forward)0.07
PEG—
EV/EBITDA1.03
EV/Revenue0.25
P/S0.01
P/B0.01
EPS (TTM)0.16
EPS (Forward)3.48
52W Range
0.001014% of range3.725
52W High3.725 USD
52W Low0.0010 USD
Profitability
Gross Margin70.01%
Oper. Margin15.94%
EBITDA Margin24.20%
Profit Margin11.26%
ROE15.26%
ROA8.78%
Growth
Revenue Growth-12.80%
Earnings Growth—
Cash Flow & Leverage
Operating CF50.70M $
CapEx (TTM)178.00K $
FCF Margin14.88%
FCF Yield1164.80%
Net Debt57.10M $
Net Debt/EBITDA0.92
Balance Sheet
Debt/Equity0.27
Current Ratio2.16
Quick Ratio1.51
Book Value/Sh19.25 USD
Cash/Share1.182 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.13.16M
Float5.91M
Insiders0.00%
Institutions54.77%
Short Interest
Short Ratio3.9d
Short % Float4.19%
Short % Out.2.71%
Shares Short350.53K
Short (prev mo.)484.16K
Technical
SMA 500.5151 (+2.9%)
SMA 2000.4638 (+14.3%)
Beta0.64
S&P 52W Chg18.16%
Avg Vol (30d)330
Avg Vol (10d)1.03K
Technical Indicators
RSI (14)56.4
MACD-0.0069
MACD Signal-0.0518
MACD Hist.+0.0449
BB Upper0.7575 USD
BB Middle0.3784 USD
BB Lower-0.0008 USD
BB Width200.45%
ATR (14)0.1350 USD
Vol Ratio (20d)7.59x